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NTENSIVE TREATMENT, including high-dose chemo therapy/radiotherapy with either allogeneic or autolo gous stem cell transplantation has been widely used in multi ple myeloma (MM) patients during the last decade and may improve long-term survival and induce long periods of un maintained disease control.1 '6 It is still controversial whether allogeneic bone marrow transplantation (allo-BMT) should be offered to younger patients with an HLA-identical sibling. In a recent retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT), no advantage could be shown for allo-BMT in general as compared with autologous stem cell transplantation (ASCT).7 A high treat ment-related mortality (TRM) in the first year after allo-BMT was the major problem in M M . However, the fact that in patients alive at 1 year after transplantation the diseasefree survival was significantly longer after allo-BMT as com pared with ASCT suggests a favorable graft-versus-myeloma remission (CR) after DLI, which has persisted in I patient for already more than 3 years.9 Both patients who received 3.3 X 10 and 1.2 X 10 T cells/kg, respectively, developed moderate graft-versus-host disease (GVHD) that was respon sive to mild immunosuppressive therapy.9
This study, which summarizes the results of DLI in a larger group of patients from BMT centers in the Nether lands, shows that this form of adoptive immunotherapy in duces response in the majority of relapsed MM patients. This observation adds further proof for the existence and benefits of a GVM effect.
MATERIALS AND METHODS
Patient characteristics. Sixty-one patients with MM received an allo-BMT from I-ILA-identical siblings from 1987 until now at four BM centers in the Netherlands. Patients who were refractory to or relapsed after allo-BMT were candidates for DLI. Patients were (GVM) effect. Recently, the existence of GVM was shown ineligible if they had a performance status 4 (World Health Organi/.amore directly by remissions occurring after donor leukocyte tion), active GVHD, severe infection, and abnormal liver or renal infusions (DLI) in patients with relapse MM after alio function. A total of 13 patients (median age at the time of first D U , BMT.8,9 We described 2 patients who achieved complete ^8 years; range, 38 to 56 years) with relapsed MM after allo-BMT were included. Two patients (patients no. 1 and 5) have been de scribed before. of 29 DLI procedures were performed in 13 patients. In patients who did not respond or relapsed after DLI, repetitive courses of DLI, sometimes with escalated T-cell doses, were undertaken. The cumulative number of T cells infused ranged from 1 X 10(,/kg to 33 X 107/kg. T-cell numbers per DLI course are listed in Table 2 .
Definition o f response and relapse. A partial remission (PR) was defined as at least 50% or more tumor reduction as measured by decrease in myeloma proteins in serum and/or urine measured at least twice and lasting for at least 2 months. In responding patients, BM evaluation had to be in agreement with myeloma protein mea surement and had to be accompanied by improvement of clinical symptoms as well. A CR was defined as the complete disappearance of myeloma proteins and absence of bone marrow monoclonal sma cells. Relapse was defined as the doubling of myeloma proteins measured at least twice and in patients with CR as the reappearance and subsequent increase of myeloma proteins.
Definition of GVHD. The clinical manifestations of acute GVHD were graded I to IV according to the criteria described by Thomas et al." Chronic GVHD was classified as limited or extensive as described by Shulman et al. 1 2 If GVHD occurred =s3 months after BMT or ss3 months after donor leukocyte infusions, it was defined as acute. If the patient had GVHD beyond 3 months, it was defined as chronic.
Analysis of chimerism. Analysis of chimerism of peripheral blood T cells and non-T cells was performed by polymerase chain reaction of tandem-repeat sequences of hypervariable regions of human DNA as described before.11 In addition, in sex-mismatched transplants, chimerism was evaluated by fluorescence in-situ hybrid ization (FISH) using X-chromosome-and Y-chromosome-specific probes. These probes were used in conjunction with T-cell-specific monoclonal antibodies, eg, CD5 and CD3, coupled to alkaline phosphatase-antialkaline phosphatase (APAAP) and cells were analyzed on cytospin slides as described before.14
RESULTS
Response. Eight of 13 (62%) patients responded. Four patients achieved a PR and 4 patients a CR. Six patients responded after the first dose of leukocytes containing be tween I X 10fi and 33 X 107 T cells/kg. Dose escalation did induce a partial remission in 2 initial nonresponding patients and a CR in 1 partially responding patient. Dose escalation had no effect in 3 nonresponding patients. It is still too early to evaluate the effect of dose escalations in 2 other patients (patients no. 12 and 13). The median time to response was 6 weeks (range, 4 to 10 weeks). Two patients relapsed bio chemically and overt clinically 5 and 14 months after DLI, respectively. The first patient (no. 4) then received 3 courses of V AD chemotherapy (vincristine, adriamycin, dexamethasone)15 followed by intermediate-dose melphalan at 70 mg/ n r intravenously (IDM )4 followed by infusion of unmanipu lated peripheral blood stem cells (PBSC; 4.6 X 106 CD34V kg) containing 14 X 107 T cells/kg. The patient went into PR, but is not assessable for response to the last DLI due to the prior chemotherapy. The other patient (no. 5) received 1 X 107 donor T cells/kg without response, followed 9 weeks later by 1 X I0B donor T cells/kg, still without response evaluated 4 weeks after the last DLI. The median response duration was 5 months (range, 2+ to 38+ months). Details of T-cell doses administered, responses in correlation with toxicity profiles, and durations of survival are shown in Table   2 Follow-up o f nonresponding patients. Patient no. 2 re ceived no further treatment and died from progressive dis ease 28 months after DLI.
Two patients were treated with chemotherapy. Patient no. 3, who had progressive symptomatic disease after the fourth DLI, showed a good clinical and partial biochemical re sponse to 3 courses of cyclophosphamide, adriamycin, and prednisone combination lasting 6 months. It is too early to evaluate the response to the current treatment with conven tionally dosed melphalan and prednisone. Patient no. 6, who had progressive symptomatic disease during and after DLI, was treated with melphalan and prednisone starting 8 months after the last DLI. The effect of chemotherapy is not yet evaluable. Patient no. 11 was rapidly progressive after the last DLI and has received palliative radiotherapy on the tho racic spine and left shoulder. Durations of survival are listed in Table 2 . Factors correlating with response to DLL Seven of the 9 patients with acute G V H D and 1 of the 4 patients without acute G VH D responded, suggesting a correlation of GVHD with response (P = .12; Fisher's exact test, two-sided). This correlation was statistically significant in the patients with chronic GVHD: 6 o f 7 patients developing chronic GVHD responded, whereas none of the 5 patients without chronic G VH D showed a response (P = .015; Fisher's exact test, two-sided).
Response was induced after 4 of 6 T-cell doses with more than 1.0 X 108/kg, whereas it occurred in only 4 of 21 Tcell doses <1.0 X 108/kg (P = .02; Fisher's exact test, twosided). One of the 2 nonresponding patients who received more than 1.2 X 108 T cells/kg did not develop GVHD. The relationship between T-cell dose, GVM, and GVHD is shown in Table 3 .
No definite conclusions could be drawn from the analysis of T-cell chimerism in relation to response to DLI. Two (responding) patients were mixed T-cell chimeras before DLI, whereas 9 other patients (3 CR, 3 PR, and 3 no re sponses [NR]) were complete donor T-cell chimeras.
O f the 8 responding patients, 4 (50%) had no GVHD with initial BMT, and in 4 o f 8 responding patients, the time interval between BMT and DLI was less than 2 years.
DISCUSSION
The antileukemic effect of GVHD and DLI is well docu mented in both acute leukemia and chronic myeloid leuke mia (C M L ).lf'"28 Also, in myeloma, incidental reports of DLI in small numbers of patients have indicated the existence of a GVM effect:8,l) Our study in a larger group of patients confirms the potency o f donor leukocytes to induce re sponses in relapsed M M after allo-BMT. Sixty-two percent (8 of 13) of our patients responded, including 4 with CR (30%). However, the ultimate response rate was 46%, be cause 2 responding patients died treatment-related early deaths due to BM aplasia. Five responding patients received systemic prednisone for treatment of GVHD. However, the Toxicity. Two patients developed BM aplasia (patients influence of corticosteroids on response was unlikely, beno. 8 and 9) and died of septicemia. In 1 patient (no. 8), cause 4 of these patients had received high-dose prednisone BM aplasia was associated with acute GVHD grade 3. The before without a response. Moreover, CR (in 4 patients) other patient (no. 9) developed severe thrombopenia (< 30 induced by prednisone alone is improbable. From the 2 pa-X 1OTL) 6 weeks and severe neutropenia 8 weeks (<1 X tients with a PR receiving prednisone, in 1 patient (the pa-I09/L) after DLI. In this patient, DLI was followed by acute dent with CR after dose escalation) myeloma protein de-of patients may therefore be partially due to the fact that the initial BMT was performed with a T-cell containing 105/kg T cells with minimal or no GVHD post transplantation. Although the presence or absence of GVHD at initial BMT did not relate with response to D LI in our series, it is possible that the outcome for non-T-cell-depleted grafts with more initial severe acute and for chronic G V H D may be less successful. In addition, responses may have occurred in some patients who would not have relapsed if they had received unmodified grafts. This may be shown by the fact that the only lasting CRs are present in 3 patients with no or very mild GVHD at initial BMT and grade III acute GVHD plus chronic GVHD after DLI.
A T-cell dose-response effect of DLI had already been shown in leukemia, especially in C M L.,8,I<) However, T-cell doses required to induce responses in MM may be higher than in CML. Patients with CM L may respond to doses as 6 low as 1 X 10 /kg. Although T-cell doses as low as 1 X clined significantly before the onset and treatment of GVHD.
lOVkg may induce GVM (patient no. 12 and the patient The other patient was progressive after CHOP chemother-described by Tricot et al8), our data indicate that 5 X 107/ apy, whereas a response was measurable at the onset of kg T cells may be preferred as the starting dose. In case of GVHD. CRs may be durable, because 1 patient is still free of disease (no signs of myeloma in blood and/or urine as determined by immunofixation and BM as determined by immunophenotyping of plasma cells) 3 years after DLI (Fig no response within 10 weeks, the infusion can be repeated with a higher number of donor lymphocytes individually adapted on preceding GVHD.
The major toxicides were secondary to acute and chronic 1). Two other patients are still in CR, with a follow-up of GVHD, which occurred in 66% and 56% of all patients and 18 and 7 months, respectively, whereas 1 patient in CR relapsed after 14 months. However, longer times of observa tion in more patients will be necessary to determine more exactly the overall response and duration after D LI in MM. The median time to document a response was 6 weeks (range, 4 to 10 weeks), which is comparable to patients with acute leukemia and C M L .I6,|,>'21
The number of donor leukocytes infused may be important in mediating a GVM effect. A T-cell dose of more than 1 X 108 cells/kg induced a response in 4 of 6 patients (67%), compared with only 4 responses after 21 DLI containing =sl X 10K T cells/kg. The T-cell dose/response relation was quite evident in 3 patients who 4 C ifter dose escalation, although it cannot be excluded completely that repeated infu sion with the lower dose would have provided the same results. Also, a late response to the previous lower dose so seemed unlikely, because in 2 previous NR pati from the prior infusion was 18 and 22 weeks, respectively (patients no. 4 and 9), whereas the third patient (no. 11 ) was progressive after initial PR to the Apart from the kind of malignancy, pre-DLI cluiracteris tics have been described that may predict response, including GVHD after initial BMT, time interval between BMT and DLI, and the occurrence of G V H D post-DLL213 In our pa tients, only the occurrence of G V H D and T-cell dose of greater than 1 X lOVkg were correlated with response. Seven of 8 responding patients developed acute G V H D and 6 of tionhsip between response and GVHD suggests that GVM in 87% and 85% of the responders, respectively. The high incidence of GVHD in the responders may be related to the high number of donor T cells that were used to achieve remission. BM aplasia developed in only 2 responding pa tients, but was fatal in both patients. Marrow aplasia in up to 50% of patients receiving DLI for relapsed C M L and acute leukemia has been reported.15, 16 Kolb et al16 showed that D LI in CR of acute leukemia or in cytogenetic relapse of CM L are less prone to severe myelosuppression. It was recently shown that persisting residual donor hematopoiesis in relapsed patients protects them from DLI-induced BM aplasia.,0 In our group of patients, only 2 were mixed T-cell chimeras, but both still had residual donor hematopoiesis at the time of DLL as indicated by analysis of peripheral blood non-T cells. GVHD grade III probably contributed to the fatal aplasia in patient no 8. In the other patients, complete donor T-cell chimerism was likely to be associated with residual normal donor hematopoiesis. This further indicates that donor hematopoiesis usually persists in relapsed M M allo-BMT and that the incidence of DLI-induced myssion may therefore be low as compared with acute ia and CML. The recent introduction of techniques to abrogate exces sive GVHD by using donor T lymphocytes transduced with the suicide gene viral thymidine kinase (TK) may be helpful 2'UI However, the close rela-7 responders assessable for evaluation developed chronic GVHD. All 5 patients with G V H D g n compared with only 1 3 re: as in 4 patients without GVHD. It is likely that the association cell dose and response is due to a close relationship between GVHD and GVM. The high success rate of DLI in our group is mediated by alloreactive T cells directed against minor present on both normal and mycells. Elimination of the TK-transduced T cells by in vivo administration of ganciclovir might abrogate the GVM V i * * * are :e ur warranted. Infusion of purified allogeneic immune cells or selective elimination of subsets of TK-transduced donor T cells may elucidate whether GVM is mediated by a specific effector population.
In conclusion, donor leukocyte infusions can induce re missions in the majority of patients with relapsed MM after allo-BMT. The dose of donor leukocytes used may be im portant for the achievement of GVM . Doses of more than 1 X 108 donor T cells gave the highest probability of response, although the optimal individual dose may vary. In MM, individually adapted therapy consisting of repeated infusions with escalating doses of donor leukocytes until maximal response is achieved may therefore be preferable. Efforts, including infusion of subsets of T cells,33 combination of DLI with cytokines such as interleukin-2, 'y,M and selective in vivo elimination of TK-transduced donor effector cells may reduce the toxicity of GVHD while preserving the GVM effect of DLL
